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Stroke remains a leading cause of human disability. Impor-
tant gains have been realized in the setting of acute ischemic
stroke, where thrombolytic and catheter-based reperfusion
therapies can substantially improve long-term behavioral
outcomes.However,mostpa-
tients with a new stroke are
not eligible for such thera-
pies because of delays in diagnosis or hemorrhagic etiology,
for example, andmanywhoare treatednonethelesshave sub-
stantial long-term disability. Additional classes of poststroke
therapy are needed.
An emerging branch of stroke therapeutics targets neural
repair. Such restorative therapies are introduced after stroke-
related injury is fixed and therefore do not aim tomodify the
initial insult. Instead, the strategy is to improve outcomes by
promoting favorable clinical neuroplasticity within surviv-
ing neural elements.1 Many categories of brain repair therapy
are under study, including small molecules, growth factors,
monoclonal antibodies, cells, activity-based therapies, telere-
habilitation, and brain stimulation.2 Several forms of brain
stimulation have been advanced. An advantage of this ap-
proach, compared with systemic administration of a drug, is
reduced toxicity given that trillions of cells outside the brain
arenotexposed.Transcranialdirect current stimulation (tDCS)
has the additional advantage that it is noninvasive, passingdi-
rect current through the scalp/skull to the brain, producing
a subthreshold modulation of resting membrane potentials,
and thereby modifying the function of distributed brain
networks.
In the current issue of JAMANeurology, Fridriksson et al3
examined the effects of tDCS on language function in pa-
tients with chronic stroke and aphasia. These authors per-
formed a double-blinded, prospective, randomized, con-
trolled clinical trial at 2 US sites. Enrolled individuals had a
history of a single ischemic stroke in the dominant left hemi-
sphereat least6monthsprior.At the timeofenrollment, study
participants had aphasia that was neither too severe (partici-
pants had to score >65% accuracy on an object naming test)
nor too mild (score on the Philadelphia Naming Test needed
to be <80%). Individuals were randomized to speech therapy
accompanied by either active or sham tDCS that was applied
during the therapy. The primary end point was the change in
the number of correctly named common objects from pre-
treatment to 1-week posttreatment.
In both study groups, speech therapy consisted of 15 out-
patient sessions of 45 minutes’ duration over a 3-week pe-
riod. Individuals in the active tDCS group also received 1 mA
of anodal tDCS, whereby two 5 × 5 cm sponges were placed,
1 ofwhich (the anode)wason the left scalpover a targeted cor-
tical region and the other of which (the cathode) was on the
right supraorbital scalp; in general, anodal tDCS increases cor-
tical excitability.4 The targeted cortical region was identified
by a functionalmagnetic resonance imaging scan obtained at
baseline, ensuring that stimulationwas centered over a func-
tionally intact left temporal lobe region, andunderscoring the
utility of using ameasure of brain function to direct details of
a restorative therapy for individual patients.5
The 2 groupswere generallywellmatched at baseline, al-
though the active tDCS group tended to have better aphasia
scores at baseline (results were little changedwhen adjusting
for this). Themean (SD) ageof all individualswas60 (10)years.
Of 74 enrolledpatients, 52 (70%)weremen, and the individu-
alshadamean (SD)of 15 (2) yearsof education.Depressionwas
uncommon. Many types of aphasia were present, the most
common being Broca aphasia. Treatment was well tolerated,
consistent with the overall published experience with tDCS:
tDCS up to 4 mA appears to be safe with no serious adverse
events andno tDCS-induced seizures across thousandsof ses-
sions in healthy individuals, individualswith a neurologic di-
agnosis, or individuals with a psychiatric diagnosis.6
Themain study findingwas that themean (SE) treatment-
related change in correct object naming was 13.9 (2.4) words
for active tDCS combined with speech therapy and 8.2 (2.2)
words for shamtDCScombinedwith speech therapy.This rep-
resents anabsolute increaseof 5.7words (95%CI, −0.9 to 12.3)
and a relative increase of 70% for active tDCS compared with
sham tDCS. The studyused a futility design,whereby thenull
hypothesis assumed a benefit for active comparedwith sham
tDCS, while the alternative hypothesis assumed no differ-
ence between active and sham tDCS. The P value for the fu-
tility hypothesis was .90.
What is themeaningof a futilityhypothesisPvalueof .90?
This indicates that the study failed to reject the null hypoth-
esis (ie, the study did not provide evidence that anodal tDCS
as used herein is futile) and so indicates that further evalua-
tionof theactive intervention iswarranted.Futilitydesignwas
bornoutofoncology researchandwasdeveloped to reject can-
didate therapies with a low probability of success. Members
of the current study team3 were among those who pioneered
this approach in neurologic studies.7 Futility trials of puta-
tive therapeutic agents may be of particular value when the
targetdisease isheterogeneous, has aprotractedorunpredict-
able course, or lacks straightforward and widely used out-
comemeasures.8 In a typical trial focused on comparative ef-
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ficacy, the null hypothesis states that the active and control
interventions have equal efficacy and is rejected if the pri-
mary outcomemeasure is significantly different between the
2groups.However, in a futility trial, thenull hypothesis is that
the active intervention will improve the outcome relative to
control by aprestatedmargin: if the active treatment doesnot
achieve this, the null hypothesis is rejected and the treat-
ment isdeemedfutile; if theactive treatmentdoesachieve this,
the null hypothesis is not rejected and the treatment is de-
clared nonfutile and thusworthy of further investigation.8 In
a futility study,data can reject thenull hypothesis butnot con-
firm it; failure to reject the null hypothesis in a futility study
is not tantamount to assigning superiority of the active treat-
ment relative to control. Instead, failure to reject the null
hypothesis suggests that it is logical to proceed with further
evaluation of the active treatment.9
Any follow-up study to the current trial might be in-
formedbyunderstandingwhichpatient featurespredict treat-
ment efficacy. Response to restorative therapies after stroke
is often highly variable, particularly for tDCS,10 in part be-
cause of large interindividual differences in stroke-related in-
jury and in poststroke plasticity. Not surprisingly, treatment
efforts to promote brain plasticity after strokeproduce incon-
sistent results.Biomarkershave thepotential todistinguishpa-
tient subgroups and thus identify personswhoare likely to re-
spond favorably to a given restorative therapy.11 In the study
by Fridriksson et al,3 baseline aphasia severity predicted the
extent of treatment-related gains. Studies from a number of
groups have consistently found that measures of neural in-
jury andneural function can substantially improveon thepre-
dictive value provided by behavioral examination and so are
useful for patient selection and stratification in restorative
stroke trials.12-14
Any future studies of tDCS combinedwith speech therapy
to improvepoststrokeaphasiawillneed toconsider severalkey
questions.Whichpopulation shouldbe enrolled? In studies of
restorative therapies after stroke, there is a tension between
enrolling a narrowly defined population to reduce interindi-
vidual variance and so retain sufficient power to detect a true
treatment effect vs enrolling a broadpopulation to insure that
results will substantially generalize. Which dose should be
studied?Thecurrent choice for therapyduration, 3weeks,was
selected tomatcha typicaldoseofoutpatient language therapy
for chronic aphasia in the United States.3 The question arises
whether a longer duration of treatmentmight produce larger
gains. Forhow long shouldpatients be assessed after therapy?
Another tension in studies of restorative therapies after stroke
is duration of follow-up: short durations are more reflective
of actual treatment effects but have lower effect because any
benefits observedmaynot be lasting. Longer durations of fol-
low-up candetect lasting gains but often reflect additional in-
fluences, suchasnewonset depressionornewstroke, that are
unrelated to the specific hypothesis under study.
What does the ability to name 13.9 more objects mean in
real life? If you are trying to order lunch or select a grand-
child’s birthday present, it canmean theworld. If you are liti-
gating a criminal case, it is likely insufficient. For most pa-
tients, this improvementmay be clinically important. Indeed
Fridriksson et al3 note that “even 1 to 2 words’ improvement
could be meaningful to some patients who have very limited
speech output.” Likely, the global outcome measures found
useful in acute stroke studies, such as the modified Rankin
Scale, would be insensitive to most behavioral gains pro-
vided by the current intervention, underscoring the impor-
tance of modality-specific end points in restorative stroke
trials.15
The study by Fridriksson et al3 thus can be said to pro-
vide no evidence that anodal tDCS as used herein and com-
bined with speech therapy is futile. The authors conclude,
rightly, that thesedataprovidemotivation toproceedwith fur-
ther study of the effect of this form of active tDCS combined
with speech therapy on aphasia outcomes poststroke. Over
time, identification of the ideal therapy intensity and dura-
tion, as well as target population, offers hope that language
function can be substantially improved in individuals with
poststroke aphasia.
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